The diagnostic value of plasma N-terminal connective tissue growth factor levels in children with heart failure

Li, Gang; Song, Xueqing; Xia, Jianguo; Li, Jing; Jia, Peng; Chen, Pengyuan; Zhao, Jian; Liu, Bin

doi:10.1017/s1047951116000196

Cited by 3 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regards to relation between CTGF and LV systolic function (EF% and FS%), the current study reported that CTGF was significantly negatively correlated with EF% and FS% measured by echocardiography. This was in agreement with Li G et al [13].…”

Section: Fig 2 Cutoff Sensitivity Specificity Positive Predictivsupporting

confidence: 93%

Plasma Levels of Connective Tissue Growth Factor in Children with Congestive Heart Failure

Wagieh¹,

Shabana

El-Serogy

et al. 2020

JAMMR

View full text Add to dashboard Cite

Objectives: Assessment of plasma level of connective tissue growth factor in congestive heart failure children, assessment of its diagnostic and prognostic role and correlate its level with clinical and echocardiographic assessment of congestive heart failure. Methods: Connective tissue growth factor level in the plasma was measured in 40 children; 20 of them have congestive heart failure, and 20 are healthy then, correlated with clinical parameters. Results: The diagnostic and prognostic value of it was evaluated. We compared its levels in both patients and healthy children. We found that connective tissue growth factor level was significantly increased in diseased children. Fractional shortening and ejection fraction correlated negatively with the plasma level of connective tissue growth factor. Heart rate, respiratory rate and calibrated integrated backscatter correlated positively with connective tissue growth factor. Connective tissue growth factor was significantly correlated with the class of heart failure according to Ross classification. Conclusions: Plasma connective tissue growth factor has a promising diagnostic and prognostic value as a biomarker for congestive heart failure in children with high sensitivity and specificity.

show abstract

Section: Fig 2 Cutoff Sensitivity Specificity Positive Predictivsupporting

confidence: 93%

Plasma Levels of Connective Tissue Growth Factor in Children with Congestive Heart Failure

Wagieh¹,

Shabana

El-Serogy

et al. 2020

JAMMR

View full text Add to dashboard Cite

show abstract

“…There is limited data in pediatric heart failure[45]. Li et al[46] studied CTGF and BNP levels in 61 children including 41 with heart failure. They report that CTGF levels were significantly increased in patients with heart failure and that the levels correlated with the severity of heart failure.…”

Section: Connective Tissue Growth Factor /Ccn2mentioning

confidence: 99%

“…They report that CTGF levels were significantly increased in patients with heart failure and that the levels correlated with the severity of heart failure. Addition of CTGF levels to NT-proBNP levels also improved ability to diagnose heart failure in children[46]. The same group has also shown significant correlation of CTGF levels with pulmonary arterial hypertension associated with CHD in children[47].…”

Section: Connective Tissue Growth Factor /Ccn2mentioning

confidence: 99%

Cardiac biomarkers in pediatric heart disease: A state of art review

Fernandes¹,

Maher²,

Deshpande³

2016

WJC

View full text Add to dashboard Cite

Every year there are more than 11000 hospitalizations related to heart failure in children resulting in significant morbidity and mortality. Over the last two decades, our understanding, diagnosis and management of pediatric heart failure is evolving but our ability to prognosticate outcomes in pediatric heart acute heart failure is extremely limited due to lack of data. In adult heart failure patients, the role of cardiac biomarkers has exponentially increased over the last two decades. Current guidelines for management of heart failure emphasize the role of cardiac biomarkers in diagnosis, management and prognostication of heart failure. It is also noteworthy that these biomarkers reflect important biological processes that also open up the possibility of therapeutic targets. There is however, a significant gap present in the pediatric population with regards to biomarkers in pediatric heart failure. Here, we seek to review available data regarding cardiac biomarkers in the pediatric population and also explore some of the emerging biomarkers from adult literature that may be pertinent to pediatric heart failure.

show abstract

“…In 12–18-month-old children diagnosed with CHD and HF, plasma levels of Growth Differentiation Factor 15 (aka, GDF-15) and beta2-microglobulin (aka, beta2-MG) were positively correlated to the severity of their cardiac function comparing HF vs. healthy controls ( 77 ). As connective tissue growth factors play an important role in several biological such as cell proliferation, angiogenesis and extracellular matrix production, the plasma-N-terminal growth factor was found significantly higher in children with HF compared to healthy volunteers and may be a promising biomarker ( 78 ). Another noteworthy protein, the cardiac-myosin-binding-protein-c (aka cMyBP-C), which is a thick-filament associated protein and a specific cardiomyocyte determinating factor of the structure and integrity of sacromeres, as well as contractile function.…”

Section: Omics Studies For Biomarker Discovery In Chdmentioning

confidence: 99%

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

Liem¹,

Cadeiras²,

Setty³

2023

Cardiovasc Diagn Ther

View full text Add to dashboard Cite

Background and Objective: Heart failure (HF) in the pediatric population is a multi-factorial process with a wide spectrum of etiologies and clinical manifestations, that are distinct from the adult HF population, with congenital heart disease (CHD) as the most common cause. CHD has high morbidity/mortality with nearly 60% developing HF during the first 12 months of life. Hence, early discovery and diagnosis of CHD in neonates is pivotal. Plasma B-type natriuretic peptide (BNP) is an increasingly popular clinical marker in pediatric HF, however, in contrast to adult HF, it is not yet included in pediatric HF guidelines and there is no standardized reference cut-off value. We explore the current trends and prospects of biomarkers in pediatric HF, including CHD that can aid in diagnosis and management.Methods: As a narrative review, we will analyze biomarkers with respect to diagnosis and monitoring in specific anatomical types of CHD in the pediatric population considering all English PubMed publications till June 2022.

show abstract

The diagnostic value of plasma N-terminal connective tissue growth factor levels in children with heart failure

Abstract: Plasma N-terminal connective tissue growth factor is a promising diagnostic biomarker for heart failure in children.

Cited by 3 publications

References 34 publications

Plasma Levels of Connective Tissue Growth Factor in Children with Congestive Heart Failure

Plasma Levels of Connective Tissue Growth Factor in Children with Congestive Heart Failure

Cardiac biomarkers in pediatric heart disease: A state of art review

Insights and perspectives into clinical biomarker discovery in pediatric heart failure and congenital heart disease—a narrative review

Contact Info

Product

Resources

About